Topkan E, Selek U, Kucuk A, & Pehlivan B. (2022). Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. Dove Medical Press.
Chicago Style (17th ed.) CitationTopkan E, Selek U, Kucuk A, and Pehlivan B. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. Dove Medical Press, 2022.
MLA (9th ed.) CitationTopkan E, et al. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. Dove Medical Press, 2022.
Warning: These citations may not always be 100% accurate.